Sisram Medical's Impressive First Half Results for 2025
Sisram Medical Ltd, a prominent player in the global wellness sector, has showcased remarkable performance recently. The company, known for its cutting-edge Energy-Based Devices (EBD) and innovative injectables, has shared its interim results for the initial six months of 2025. This announcement reflects a strong commitment to advancing medical aesthetics and enhancing consumer wellness.
Key Financial Highlights
During the reporting period, Sisram reported a revenue figure of US$165.5 million, showing a slight decline of 1.9% year-over-year. Despite this dip, the injectables division recorded a remarkable growth of 218.1%, contributing US$14.4 million to the overall revenue. International markets also showed resilience with revenues hitting US$108.9 million, an increase of 7.1% year-over-year, particularly enjoying a 17.6% growth in the APAC sector. However, the company faced a decrease in gross margin, sliding from 62.4% to 60.0% due to increased production costs and other factors.
Innovative Advancements in EBD
Sisram continues to lead in the domain of non-invasive body contouring through its Alma Accent Prime platform, which has been validated by peer-reviewed research. This platform has opened new commercial channels on a global scale. Furthermore, Alma Harmony continues to exceed industry expectations, solidifying Sisram's position in advanced aesthetic solutions.
The company's expansion beyond mere energy technologies has introduced novel concepts that create an integrated patient journey. Notably, Universkin by Alma has gained traction in North America, receiving enthusiastic feedback for its AI-assisted skincare solutions. The company has also rolled out the Alma IQ intelligent skin analysis platform worldwide, enhancing treatment planning and patient interaction.
Injectables: A Growing Business Segment
The performance of Sisram's injectables line marks a pivotal moment for the company, facilitating its transition from R&D to robust commercialization. The launch of Profhilo, a pioneering hyaluronic acid-based bioremodeling product in Thailand, has propelled sales and profitability, while preparations are underway for the launch of DAXXIFY—a long-lasting botulinum toxin type A product—within mainland China.
Additionally, Sisram is bolstering its commercial presence with the Revanesse filler series by establishing specialized teams across various key markets, including the UK and DACH regions, along with Australia and New Zealand. These initiatives reflect the company's commitment to robustly advancing its partnerships and product offerings.
A Glocalized Approach for Sustainable Growth
In an effort to pivot towards a more sustainable model, Sisram has embraced a glocalization strategy. This approach enables the company to blend global resources with local market knowledge, fostering high-quality growth through localized operations.
APAC continues to act as a vital growth driver for Sisram, with a 17.6% revenue increase largely attributed to strong performances in Thailand and South Korea. By creating a local ecosystem encompassing R&D, manufacturing, and sales in China, the company enhances supply chain resilience and reinforces margins.
Future Outlook
As Sisram looks ahead to the latter half of 2025, it anticipates improved revenue and net profit performance. The company plans to strengthen its corporate leadership within APAC and North America, focusing on innovation and operational excellence. The anticipated launch of DAXXIFY in China is expected to synergistically complement its global injectables portfolio and elevate Sisram's growth trajectory.
Mr. Liu Yi, the Chairman and Executive Director, expressed confidence in the company's future: "We are committed to developing an integrated growth model that combines technological innovation with ecosystem expansion. The upcoming DAXXIFY launch in mainland China represents a significant milestone in our journey to establishing a strong second growth engine. By leveraging advancements in AI and material science, we are redefining the medical aesthetics landscape."
About Sisram Medical Ltd
Sisram Medical Ltd is a recognized leader in medical aesthetics, operating with over 25 years of expertise in energy-based devices (EBD). The company's ecosystem encompasses EBD technologies, injectables, diagnostics, and relevant solutions, serving clientele in more than 110 countries. Owned predominantly by Fosun Pharma, Sisram’s innovative products redefine safety and efficacy standards for aesthetic care.
Frequently Asked Questions
What were Sisram Medical's revenue figures for the first half of 2025?
Sisram Medical reported a revenue of US$165.5 million for the first half of 2025.
How much growth did the injectables segment achieve?
The injectables segment saw an impressive growth of 218.1%, reaching US$14.4 million.
What innovations did Sisram introduce in the EBD market?
Sisram introduced the Alma Accent Prime platform and the Alma IQ intelligent skin analysis platform to enhance patient care.
What is Sisram's strategy for future growth?
Sisram is focusing on a glocalization model, combining global resources with local market insights for sustainable growth.
Who is the majority owner of Sisram Medical Ltd?
Sisram Medical Ltd is majority-owned by Fosun Pharma, a leading healthcare firm in China.
